In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report). The company’s shares closed yesterday at $109.50.

Short interest in Axsome Therapeutics Inc (NASDAQ:AXSM) decreased during the last reporting period, falling from 6.62M to 5.75M. This put 14.22% of the company's publicly available shares short.

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

Former CFPB director says Trump ‘begging for another financial crisis’ by closing agency The Consumer Financial Protection Bureau has been shut down by President Trump, at least for this week ...

Large areas of cloud will persist through the night but still with a few clear breaks developing in places. A dry and chilly night. Wednesday Little change tomorrow, as skies will remain mostly ...

After hours: February 10 at 6:51:12 p.m. EST ...

After hours: February 10 at 6:51:12 p.m. EST ...

After hours: February 7 at 6:43:15 PM EST ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...